Invitae to acquire ArcherDX for $1.4 billion

Create PDF

June 30, 2020—Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company.

The combined company will integrate germline testing, tumor profiling, and liquid biopsy technologies and services in a single platform to enable precision approaches from diagnostic testing to therapy optimization and monitoring, expanding access to personalized oncology.